The first OPTIMA face-to-face meeting was held on 17-18 June in Amsterdam, the Netherlands. It was the first time all members of the consortium had been able to meet in person and build relationships – and it was a great success.
OPTIMA is an Innovative Health Initiative (IHI)-funded project. Its vision is for every patient to have access to the most up-to-date individualised treatments and therapies. The project works to strengthen shared decision-making through dynamic computer-interpretable guidelines (CIGs), innovative access to broad data sets and tools – driven by artificial intelligence (AI).
ELF is excited to be facilitating the work of the Patient and Public Advisory Board (PPAB) and bringing together patients from three different cancer types, together with the European Cancer Patient Coalition (ECPC). At this stage we are all learning more about the pros and cons of AI and what the possibilities are. The PPAB highlighted some of the worries and concerns from the patient community and what they want to see as practical outcomes of the project.
Please contact ELF if you are interested in this project and want to learn more: firstname.lastname@example.org
The July 2022 patient spotlight is on Marjo Forsblom from Finland, who is living with lung cancer. Marjo is a member of the Patient/Public Advisory Board (PPAB) for OPTIMA and attended the first face-to-face meeting.
Read about her experiences and her involvement in the project.Read the spotlight
OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
The views communicated within are those of OPTIMA. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.